Sanofi-Aventis to end deal with PDI

Share this article:
Contract sales provider PDI said Sanofi-Aventis would end its $20 million sales agreement with the firm, effective Dec. 1. The deal was set to expire Dec. 31, PDI said. The end of the firm’s Sanofi-Aventis deal comes a month after GlaxoSmithKline decided not to renew a $65 million to $70 million contract with PDI for 2007. In April, AstraZeneca also ended a $65 million to $70 million agreement with PDI, affecting approximately 800 field representatives. PDI “has been significantly impacted” as the world’s top pharma companies re-evaluate their commercial models, CEO Michael Marquad said in a statement. “The decisions our customers have made have been based upon this reassessment and not related to the performance of our sales teams.”

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions